Список литературы

Поставить закладку

1. 1. 1. Jacobsen SJ, Girman CJ, Lieber MM. Natural history of benign prostatic hyperplasia. Urology. 2001;58(6 Suppl 1):5–16.
    2. Пушкарь Д.Ю., Раснер П.И. Симптомы нижних мочевыводящих путей и доброкачественная гиперплазия предстательной железы. // Урология 2006; № 3 (приложение): с. 4-18.
    3. Emberton M, Fitzpatrick JM, Garcia-Losa M, Qizilbash N, Djavan B. Progression of benign prostatic hyperplasia: systematic review of the placebo arms of clinical trials. BJU Int. 2008;102:981–6.
    4. Management of Non-neurogenic Male LUTS. European Association of Urology Guidelines. https://uroweb.org/guidelines/management-of-non-neurogenic-male-luts
    5. Management of Benign Prostatic Hyperplasia. American Urological Association Guidelines. https://www.auanet.org/benign-prostatic-hyperplasia-(2010-reviewed-and-validity-confirmed- 2014)
    6. Abrams P., Cardozo L., Fall M., Griffiths D., Rosier P., Ulmsten U., van Kerrebroeck P., Victor A., Wein A. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; № 21(2):167-78.
    7. Аденома простаты. Урология. Национальное руководство. Ред. Н.А. Лопаткин. М.: Гэотар-Медиа, 2009; с. 852-889.
    8. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; № 132 (3): 474-479.
    9. Lytton B., Emery J.M., Harvard B.M. The incidence of benign prostatic hypertrophy. J Urol 1968; № 99 (5): 639-645.
    10. Сивков А.В. Значение ультразвуковых исследований органов мочеполовой системы при профилактических осмотрах. Диссертация канд. мед. наук., М., 1998, с. 1- 279.
    11. Abrams P, de la Rosette J, Griffiths D, Koyanagi T., Nordling J., Park Y-C., Schafer W., Zimmern P. The diagnosis of bladder outlet obstruction: Urodynamics. In: Cockett AT, Khouri S, Aso Y, Chatelain C., Denis L., Griffiths K., Murphy G. (eds). Proceedings of the 3rd International Consultation on BPH. Paris, SCI, 1995, c. 299–356.
    12. Torlakovic G., Grover V.K., Torlakovic E. Easy method of assessing volume of prostate adenocarcinoma from estimated tumor area: using prostate tissue density to bridge gap between percentage involvement and tumor volume. Croat Med J 2005; № 46 (3):423-428.

1. 1. 1. Irwin D.E., Milsom I., Hunskaar S., Reilly K., Kopp Z., Herschorn S., Coyne K., Kelleher C., Hampel C., Artibani W., Abrams P. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. Eur Urol 2006; № 50 (6):1306–14.
    2. Chapple C., Abrams P. Lower Urinary Tract Symptoms. In: Male Lower Urinary Tract Symptoms (LUTS). Editors Societe Internationale d’Urologie (SIU). Fukuoka, Japan, 2012. p. 44-60.
    3. Taoka R., Kakehi Y. The influence of asymptomatic inflammatory prostatitis on the onset and progression of lower urinary tract symptoms in men with histologic benign prostatic hyperplasia. Asian J Urol 2017; № 4 (3):158-163.
    4. Ezz el Din K., Kiemeney L.A., de Wildt M.J., Debruyne F.M., de la Rosette J.J..Correlation between uroflowmetry, postvoid residue, and lower urinary tract symptoms as measured by the International Prostate Symptom Score. Urology 1996; № 48 (3):393-397.
    5. Barry M.J., Fowler F.J. Jr., O'Leary M.P., Bruskewitz R.C., Holtgrewe H.L, Mebust W.K., Cockett AT. The American Urological Association symptom index for benign prostatic hyperplasia. The Committee of the American Urological Association. J Urol 1992; № 148 (5):549–57.
    6. D'Silva K.A., Dahm P., Wong C.L. Does this man with lower urinary tract symptoms have bladder outlet obstruction?: The Rational Clinical Examination: a systematic review. JAMA 2014; № 312 (5):535-42.
    7. Milsom I., Abrams P., Cardozo L., Roberts R.G., Thüroff J., Wein A.J. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; № 87 (9):760–6.
    8. Tikkinen K.A., Johnson T.M. Tammela T.L. Sintonen H, Haukka J, Huhtala H, Auvinen A.Nocturia frequency, bother, and quality of life: how often is too often? A population-based study in Finland. Eur Urol 2010; № 57 (3): 488-496.
    9. Van Venrooĳ G.E., Eckhardt M.D., Gisholf K.W., Boon T.A. Data from frequency-volume charts versus symptom scores and quality of life score in men with lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2001; № 39 (1):42–47.
    10. Yap T.L., Cromwell D.C., Emberton M. A systematic review of the reliability of frequency- volume charts in urological research and its implications for the optimum chart duration. BJU Int 2007; № 99 (1): 9-16.

1. 1. 1. Cornu J.N., Abrams P., Chapple C.R., Dmochowski R.R., Lemack G.E., Michel M.C., Tubaro A., Madersbacher S. A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management - a systematic review and meta-analysis. Eur Urol 2012; № 62 (5): 877-90.
    2. Bosch J.L., Bohnen A.M., Groeneveld F.P. Validity of digital rectal examination and serum prostate specific antigen in the estimation of prostate volume in community-based men aged 50 to 78 years: the Krimpen Study. Eur Urol 2004; № 46 (6):573-9.
    3. Weissfeld J.L., Fagerstrom R.M., O'Brien B.; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. Quality control of cancer screening examination procedures in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 2000; № 21 (6 Suppl): 390-9.
    4. Dong F., Kattan M.W., Steyerberg E.W., Jones J.S., Stephenson A.J., Schröder F.H., Klein E.A. Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice. J Urol 2008; № 180(1):150-4.
1. 1. 1. Catalona W.J., Partin A.W., Slawin K.M., Brawer M.K., Flanigan R.C., Patel A., Richie J.P., deKernion J.B., Walsh P.C., Scardino P.T., Lange P.H., Subong E.N., Parson R.E., Gasior G.H., Loveland K.G., Southwick P.C. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998; № 279 (19): 1542-7.
    2. Carvalhal G.F., Smith D.S., Mager D.E., Ramos C., Catalona W.J. Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng./ml. or less. J Urol 1999; № 161 (3): 835-9.
1. 1. 1. Catalona W.J., Richie J.P., Ahmann F.R., Hudson M.A., Scardino P.T., Flanigan R.C., DeKernion J.B., Ratliff T.L., Kavoussi L.R.. Dalkin B.L, Waters W.B., MacFarlane M.T., Southwick P.C. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994; № 151 (5): 1283-90.
    2. Bohnen A.M., Groeneveld F.P., Bosch J.L. Serum prostate-specific antigen as a predictor of prostate volume in the community: the Krimpen study. Eur Urol 2007; № 51 (6):1645-52.
    3. McConnell J.D., Roehrborn C.G., Bautista O.M., Andriole G.L. Jr., Dixon C.M., Kusek J.W., Lepor H., McVary K.T., Nyberg L.M. Jr., Clarke H.S., Crawford E.D., Diokno A., Foley J.P., Foster H.E., Jacobs S.C., Kaplan S.A., Kreder K.J., Lieber M.M., Lucia M.S., Miller G.J., Menon M., Milam D.F., Ramsdell J.W., Schenkman N.S., Slawin K.M., Smith J.A.; Medical Therapy of Prostatic Symptoms (MTOPS) Research Group.The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; № 349 (25):2387-98.